Gray Jhanelle, Murren John, Sharma Anupama, Kelley Scott, Detterbeck Frank, Bepler Gerold
Department of Thoracic Oncology, Yale-New Haven Medical Center, New Haven, Connecticut, USA.
J Thorac Oncol. 2007 Jun;2(6):571-3. doi: 10.1097/JTO.0b013e31805fea51.
Bowel metastasis and perforation in patients with non-small cell lung cancer is rare. Bevacizumab has emerged as a new therapy in the treatment of metastatic non-small cell lung cancer. Bowel perforation associated with its use has been described in colon and ovarian cancers. The exact mechanism by which perforation occurs is under debate, and many theories exist. In this report, we present the first known case of visceral perforation in a patient with metastatic non-small cell lung cancer after treatment with bevacizumab.
非小细胞肺癌患者发生肠转移和穿孔较为罕见。贝伐单抗已成为治疗转移性非小细胞肺癌的一种新疗法。其使用相关的肠穿孔在结肠癌和卵巢癌中已有报道。穿孔发生的确切机制仍在争论中，存在多种理论。在本报告中，我们呈现了首例已知的转移性非小细胞肺癌患者在接受贝伐单抗治疗后发生内脏穿孔的病例。
